Embryonal fyn-associated substrate

Embryonal Fyn-associated substrate
Identifiers
Symbols	EFS ; CAS3; CASS3; EFS1; EFS2; HEFS; SIN
External IDs	OMIM: 609906 HomoloGene: 4284 GeneCards: EFS Gene
Gene ontology Molecular function • SH3 domain binding • protein domain specific binding Cellular component • cytoplasm Biological process • cell adhesion • intracellular signal transduction Sources: Amigo / QuickGO
Orthologs
Species	Human	Mouse
Entrez	10278	13644
Ensembl	ENSG00000100842	ENSMUSG00000022203
UniProt	O43281	Q64355
RefSeq (mRNA)	NM_001277174	NM_010112
RefSeq (protein)	NP_001264103	NP_034242
Location (UCSC)	Chr 14: 23.36 – 23.37 Mb	Chr 14: 54.92 – 54.93 Mb
PubMed search

Embryonal fyn-associated substrate is a protein that in humans is encoded by the EFS gene. It is also known as CASS3.^[1]

History and discovery

EFS (Embryonal Fyn-associated Substrate), also known as SIN (Src INteracting or Signal Integrating protein) was originally identified using cDNA library screening of mouse embryonal libraries for proteins containing SH3-interacting domains, or interacting with the SRC SH3 domain, in two independent studies by Ishino et al.^[2] in 1995 and Alexandropoulos et al.^[3] in 1996.

In humans, the 561 amino acid EFS protein acts as a scaffolding protein for cell signaling based on interactions with SRC, FAK, and other proteins, and has been linked to roles in the function of the immune system, and the development of cancer.

Gene

The chromosomal location of the EFS gene is 14q11.2 and its genomic coordinates are 14:23356400-23365633 on the reverse strand in GRChB38p2 (Genome Reference Consortium Human Build 38 patch release 2).^[1] According to the Human Genome Organization (HUGO) Gene Nomenclature Committee (HGNC) its approved symbol is EFS and its synonyms are "Cas scaffolding protein family member 3", CASS3, EFS1, EFS2, HEFS and SIN. The official Gene IDs assigned to EFS are 16898 (HGNC), 10278 (Entrez Gene) and ENSG00000100842 (Ensembl).

In humans, at least three transcript variants are known for EFS: isoform 1, containing 6 exons end encoding the full-length protein with 561 amino acids; isoform 2, containing 5 exons and encoding a shorter protein (468 amino acids in length); and isoform 3, containing 6 exons and encoding the shortest protein (392 amino acids).

Little is known about the transcriptional regulation of EFS, but several transcriptional regulators for EFS have been proposed based on consensus binding sites in its promoter region for ATF (Activating transcription factor), NF-κβ, NF-κβ1, GATA-3, C/EBPα (CCAAT/enhancer-binding protein alpha), glucocorticoid receptors α and β, and p53.^[4] Expression of isoforms 1 and 2 has been detected in multiple tissues, with maximal expression in the placenta, and the embryonal central nervous system, heart, testes and lungs.^[5] Although its expression has been reported as lower in thymus and lymphocytes, functional studies of EFS to date have best defined it as important for immune system function.^[6][7][8] One screen for implantation-related genes regulated by progesterone found that EFS was downregulated by 17β-estradiol and progesterone in explants of late proliferative phase endometrium.^[9]

Protein family

EFS is a member of the CAS (Crk-Associated Substrate) family of proteins. In humans and mammals, this group consists of four members: p130Cas/BCAR1, NEDD9/HEF1, CASS4 and EFS.^[10] There are no paraloguous genes for this family in yeasts and fungi, diploblasts and nematodes such as C. elegans. A single ancestral member is found in Drosophila.^[11][11]

Structure

Table 1. EFS structure.

Domain	Position	Length	Function
N-terminal	1 - 4	4 aa	This region has no assigned function
SH3-domain	5-68	64 aa	Binds to proline-rich motif containing proteins, such as FAK,[12] PTK2B,[13] C3G,[14] PTP-PEST,[15] PTP1B,[16] CIZ[17] and FRNK.[18]
SH2-binding region	69 - 350	282 aa	Contains YxxP motifs capable of being phosphorylated on tyrosine residues, then binding SH2 domains.
Serine rich domain	351 - 488	138 aa	Conserved domain structure encompassing 4 α-helices bundle has a docking function.
C-terminal	489 - 561	73 aa	Conserved domain structure encompassing 4 α-helices bundle has a docking function; homo- or heterodimerization; focal adhesion targeting.

As the member of CAS protein family, EFS shares common structural characteristics with other members of the family. This includes 4 defined domains (summarized in Table 1):

• An N-terminal SH3 domain that is highly conserved among the 4 CAS family members, and highly conserved throughout evolution (amino acids 5-68 for human EFS). SH3 domains bind to proline-rich motif containing proteins.^[2] The amino acid sequences of the SH3 domains are 70% identical among human EFS, BCAR1, and NEDD9, making this the most highly conserved domain for the whole protein family.^[5] Notably, the murine and human EFS SH3 domains are 100% identical, while the rest of the amino acid sequences of mouse and human EFS are only 78% identical.^[5] Important binding partners for this region include FAK,^[12] PTK2B,^[13] C3G,^[14] PTP-PEST,^[15] PTP1B,^[16] CIZ,^[17] and FRNK.^[18]
• Central “substrate domain” containing multiple repeats of tyrosine residues embedded within specific conserved sequences (YxxP) (amino acids 69-350 for human EFS).^[19] This region contains 9 such binding sites, in contrast to family members BCAR1 and NEDD9 (20 and 18 motifs, respectively) and similar to CASS4 (estimated at 10 such motifs).^[11] Once phosphorylated by SRC or other kinases, these tyrosine motifs are bound by the SH2 domains of signaling proteins. Important binding partners for this region include Crk1/2 and Crk-L, a Crk1 paralogue.^{[5][11][20][21]}
• A serine-rich domain encompassing a 4 α-helix bundle (amino acids 351-488 for human EFS). Although primary amino acid sequence shows considerable divergence versus other CAS family members in this region, structural analysis predicts that this bundle has a highly conserved fold and provides a docking site for family members.
• A C-terminal domain (489-561 amino acids in human EFS) is highly conserved between family members at both primary amino acid sequence and predicted fold.^[11] All CAS proteins except CASS4 contain a YDYVHL motif within this domain, which is an important binding site for the Src SH2 domain. This region is considered to possess a homo- or heterodimerization ability.

There are three protein isoforms of human Efs. hEfs1 and hEfs2 were identified by Ishino et al.^[5] hEFS1 (561 aa) represents the human counterpart of mouse embryonal Efs (mEfs1) originally identified. hEFS1 and mEfs1 are 80% identical in their amino acid sequences and 100% identical within the SH3 domain. hEFS2 (468 aa) is identical to hEFS1, except for its lack of the SH3 domain. hEFS3 (392 aa) also lacks a functional SH3 domain and has the same C-terminus and short N-terminal amino acid tail as the full-length protein.^[22][23] Although little functional analysis of hEFS2 has been performed, speculatively, given lack of an SH3 domain, abundant hEFS2 may inhibit hEFS1 signaling by titrating partner proteins.^[5] As of 2015, there has been no functional analysis of hEFS3.

Function

Figure 1. Scheme, representing major proteins interacting with EFS through highly conserved motifs.

As a member of the CAS protein family, EFS is a multi-domain docking molecule that lacks any known enzymatic activity, but instead mediates signaling by promoting protein–protein interactions through conserved sequence motifs (Figure 1).^[5][24][25]

An important role of EFS as a CAS-family member function is transmission of integrin-initiated signals from the extracellular matrix to downstream effectors, leading to reorganization of the actin cytoskeleton and changes in motility and invasion.^[26] The SH3 domain is a point of contact with polyproline sequences on focal adhesion kinase (FAK).^[27] or the related kinase PTK2B, also known as RAFTK/Pyk2/CAKβ. Typically, phosphorylation of the C-terminal region of CAS proteins by FAK or PTK2B creates a binding site for the SH2 domain of a SRC-family protein, which then hyper-phosphorylates the substrate domain, allowing the CAS protein to function as a scaffold^[28] for other proteins including CRK proteins and C3G, a guanine nucleotide exchange factor (GEF) for RAP1.^[29] PTP-PEST, a soluble protein tyrosine phosphatase that is ubiquitously expressed in mice both during embryonic development and in adult tissues, opposes FAK and PTK2B activity, as it dephosphorylates PTK2B, FAK and CAS family members, among other proteins.^[30] The PTP-PEST proline-rich sequence ³³²PPKPPR³³⁷ has been shown to interact directly with the SH3 domain of members of EFS and another CAS protein, NEDD9.^[31]

In normal untransformed cells, EFS acts as a SRC family kinase substrate in neurite outgrowth,^[32] a process that is dependent on activity of SRC kinases. Reciprocally, EFS activates SRC signaling through c-CRK and RAP1.^[29] Further, SRC directly phosphorylates residues Y576 and Y577 tyrosine sites on the EFS, enhancing targeting FAK, and eventually the solubility and/or stability of the complex.^[29] Through SRC, EFS may also negatively regulate expression of E-cadherin at adherens junctions, a function that has been reported for other CAS proteins (NEDD9 and BCAR1);^[33] however, this point has not been directly established for EFS.

Disease association

The well-studied CAS proteins BCAR1 and NEDD9 have important roles in cancer and other pathological conditions, which have been addressed in many studies and reviews.^{[10][25][28][34][35]} EFS has attracted less study. However, the conserved functional properties of EFS relevant to cellular adhesion and migration, and RTK signaling, suggest changes in activity of this protein may also be relevant to cancer and other disease states, influencing prognosis and therapeutic response. The changes in EFS expression and post-translational modification in the context of disease discussed below are summarized in Table 2.

Disease	Study finding for EFS
Crohn's disease	The study linked EFS gene to Crohn’s disease (p-value 0.039) in humans.[36]
Rheumatic fever susceptibility	Significantly increased expression after stimulation of peripheral blood mononuclear cells from patients with rheumatoid heart disease.[37]
Prostate cancer	CpG site hypermethylation of EFS was associated with prediction of biochemical, local, and systemic recurrence of prostate cancer.[38] Decreased EFS expression was shown in advanced prostate cancer compared to normal tissue, which correlated with high metastatic potential.[39]
Uveal melanoma	High frequency of promoter CpG site methylation and association with a higher risk of metastatic progression.[22]
HER2+ breast cancer	EFS may play a role in trastuzumab resistance mechanism.[40]
Prolactinoma	EFS may be involved in stem cell regulation, tumor cell invasion, tumor recurrence, and drug resistance.[41]
Gestational choriocarcinoma	Located in a frequently amplified chromosomal region along with >100 other genes.[42]
Glioblastoma multiforme	One of the genes differentially expressed in two sub-groups of glioblastoma multiforme defined by gene expression profile.[43]
Chediak-Higashi syndrome	Direct interaction with LYST protein, which is associated with lysosomal trafficking.[23]
Human endometrium expression profiling	Down regulated by 17β-estradiol and progesterone in explants of late proliferative phase endometrium.[9]

Role in inflammation and T-Cell function

EFS regulates T-cell function and maturation, preventing expansion of autoreactive clones and pathological immune responses. Two studies that have reported that EFS expression in medullar thymus epithelial cells is important for negative selection of T-cells during their development,^[6][7][8] which implies an important role of EFS in maintaining immune homeostasis and autoimmunity prevention. In these studies, mice with defective EFS progressed normally during embryogenesis but then developed massive inflammatory lesions in multiple tissues that bore a striking histological resemblance to inflammatory bowel diseases such as Crohn’s disease. Mechanistically, EFS expressed in medullary thymic epithelial cells (mTECs) is crucial for their functional maturation and growth factor-mediated expansion. mTECs are important for proper T-cell maturation and negative selection of autoreactive clones, required for development of immunological self-tolerance.

EFS has mostly a repressive role of EFS on processes associated with the activation of mature T-cells, including IL-2 pro-inflammatory cytokine secretion and IL-2-dependent clonal expansion of T cells.^[7][44] Upon T-cell receptor (TCR) stimulation, EFS dephosphorylation and release of the SRC family kinase FYN and phospholipase C-γ normally lead to self-limitation of the immune response. Consistent with this mechanism, EFS overexpression in T cell-derived cell lines decreased IL-2 concentration in supernatants in response to TCR stimulation,^[44] while T cells derived from mice lacking EFS gene showed increased IL-2 production.^[7] A dual role of EFS in mature T cells function has been proposed because both overexpression and siRNA knockdown of this protein in cell models resulted in decreased transcriptional activation of IL-2 dependent promoters following TCR stimulation.^[44]

Altered EFS function has been associated with various human immunopathological conditions. Although an initial genome-wide association studies (GWAS) study of Crohn’s disease did not identify EFS,^[45] EFS single nucleotide polymorphisms (SNPs) were subsequently linked to Crohn’s disease.^[36] SNPs linked to EFS are trans-acting, potentially affecting the level of EFS expression but not its coding sequence.^[46]

Another study suggested that EFS might contribute to acute rheumatic fever susceptibility.^[37] In this work, peripheral blood mononuclear cells (PBMCs) from patients with rheumatoid heart disease (RHD) and control subjects that had never experienced acute rheumatoid fever were stimulated with rheumatogenic and non-rheumatogenic group A streptococci (GAS) strains. EFS was one of only four genes with significantly increased expression in both arms of the study: 1) RHD patient versus control PBMCs after stimulation of both groups with rheumatogenic GAS and 2) RHD patient PBMC stimulated with rheumatogenic versus non-rheumatogenic GAS. Another study has implicated EFS in the Chediak-Higashi syndrome (CHS).^[23] This rare and severe autosomal recessive disorder associated with partial albinism, peripheral neuropathy, mild coagulation defects and propensity to recurrent bacterial and fungal infections, caused by incomplete phagocytosis due to failure in phagolysosome formation. This work identified a direct interaction in vitro and in vivo between EFS and LYST (lysosomal trafficking regulator, aka CHS1 - Chediak-Higashi syndrome 1), a large protein that regulates the intracellular trafficking of proteins through endosomes that is mutated in CHS. These results may imply the role of EFS as a disease progression modifier, although further testing and establishment of mechanism is necessary.

Cancer

At the level of EFS mRNA expression, the local and systemic recurrence of prostate cancer is associated with CpG site hypermethylation of number of genes, including FLNC and EFS (p ≤ .03), both genes involved in cell attachment,^[38] and is predicted to result in reduction of gene expression. EFS expression was strongly downregulated in hormonal therapy resistant PC346DCC, PC346Flu1 and PC346Flu2 prostate cancer cells compared to therapy responsive PC346C cells.^[47] Another study found that decreased EFS mRNA expression levels are observed in higher Gleason score prostate cancer samples.^[48] Low EFS expression also correlated with malignant behavior of the PC-3 and LNCaP prostate cancer cells.^[39]

In another study, methylation of the EFS CpG island was observed in 69% of cases of uveal melanoma (UM) and only UM with EFS methylation gave rise to metastases.^[22] RT-PCR expression analysis revealed a significant inverse correlation between EFS mRNA expression with EFS methylation in UM. EFS methylation was tissue-specific with full methylation in peripheral blood cells, but no methylation in other tissues such as fetal muscle, kidney and brain.

The EFS gene is one of more than 100 of the genes located in a centromeric 10.21 Mb “minimal critical region” on Chromosome 14 that are highly expressed in gestational choriocarcinoma.^[42] The EFS mRNA was also identified as differentially expressed in two of the three groups of glioblastoma multiforme as identified by gene expression profiles (GEPs).^[43] EFS was differentially expressed in the GEP1 and GEP3 groups, which were associated with worse prognosis, with more significant cytogenetic abnormalities and genomic instabilities observed in this groups.

At the level of the EFS protein, a study of BT474 breast cancer cells found significant increases in expression of EFS and other proteins relevant to SRC kinase signaling, including CDCP1/Trask and Paxillin, in trastuzumab (Herceptin) resistant versus sensitive cells^[40] Importantly, EFS knockdown with siRNA restored trastuzumab sensitivity.^[40] Reflecting the importance of post-translational modification of CAS proteins, in a study of cell lines and tumor tissue in malignant melanoma, EFS phosphorylation and activity significantly decreased (p<0.05) in response to vemurafenib treatment in BRAF wild-type melanoma tumors comparing to ones with BRAF (V600E-vemurfenib resistant) mutation.^[49] Finally, in a 2013 study of castration-resistant prostate cancer, EFS was identified as having significantly increased gross phosphorylation levels in samples from androgen-deprived (AD), long-term AD treated, or castration-resistant prostate carcinoma xenografts, versus in androgen deprivation therapy-naıve xenografts^[50]

Clinical significance

Based on the above discussion, it is possible that therapeutic benefits can be achieved by using EFS expression or phosphorylation as a marker of disease progression and prognosis in some forms of cancer. Further assessment of EFS expression, mutational status, and potential polymorphic variants may be of use in understanding the biology and developing treatment strategies for immune system pathologies such as CHS. There are currently no therapeutic approaches targeting EFS, and given the protein lacks a catalytic domain and extracellular moieties, it may be challenging to generate such agents.

References

1. "Entrez Gene: Cas scaffolding protein family member 3".
2. Ishino M, Ohba T, Sasaki H, Sasaki T (Dec 1995). "Molecular cloning of a cDNA encoding a phosphoprotein, Efs, which contains a Src homology 3 domain and associates with Fyn". Oncogene 11 (11): 2331–8. PMID 8570184.
3. Alexandropoulos K, Baltimore D (Jun 1996). "Coordinate activation of c-Src by SH3- and SH2-binding sites on a novel p130Cas-related protein, Sin". Genes & Development 10 (11): 1341–55. doi:10.1101/gad.10.11.1341. PMID 8647432.
4. "EFS (Human)". SABiosciences.
5. Ishino M, Ohba T, Inazawa J, Sasaki H, Ariyama Y, Sasaki T (Oct 1997). "Identification of an Efs isoform that lacks the SH3 domain and chromosomal mapping of human Efs". Oncogene 15 (14): 1741–5. doi:10.1038/sj.onc.1201346. PMID 9349509.
6. Donlin LT, Roman CA, Adlam M, Regelmann AG, Alexandropoulos K (Dec 2002). "Defective thymocyte maturation by transgenic expression of a truncated form of the T lymphocyte adapter molecule and Fyn substrate, Sin". Journal of Immunology 169 (12): 6900–9. doi:10.4049/jimmunol.169.12.6900. PMID 12471123.
7. Donlin LT, Danzl NM, Wanjalla C, Alexandropoulos K (Dec 2005). "Deficiency in expression of the signaling protein Sin/Efs leads to T-lymphocyte activation and mucosal inflammation". Molecular and Cellular Biology 25 (24): 11035–46. doi:10.1128/MCB.25.24.11035-11046.2005. PMID 16314525.
8. Danzl NM, Donlin LT, Alexandropoulos K (May 2010). "Regulation of medullary thymic epithelial cell differentiation and function by the signaling protein Sin". The Journal of Experimental Medicine 207 (5): 999–1013. doi:10.1084/jem.20092384. PMID 20404100.
9. Dassen H, Punyadeera C, Kamps R, Klomp J, Dunselman G, Dijcks F, de Goeij A, Ederveen A, Groothuis P (Apr 2007). "Progesterone regulation of implantation-related genes: new insights into the role of oestrogen". Cellular and Molecular Life Sciences 64 (7-8): 1009–32. doi:10.1007/s00018-007-6553-9. PMID 17404688.
10. Tikhmyanova N, Little JL, Golemis EA (Apr 2010). "CAS proteins in normal and pathological cell growth control". Cellular and Molecular Life Sciences 67 (7): 1025–48. doi:10.1007/s00018-009-0213-1. PMC 2836406. PMID 19937461.
11. Singh MK, Dadke D, Nicolas E, Serebriiskii IG, Apostolou S, Canutescu A, Egleston BL, Golemis EA (Apr 2008). "A novel Cas family member, HEPL, regulates FAK and cell spreading". Molecular Biology of the Cell 19 (4): 1627–36. doi:10.1091/mbc.E07-09-0953. PMC 2291417. PMID 18256281.
12. Minegishi M, Tachibana K, Sato T, Iwata S, Nojima Y, Morimoto C (Oct 1996). "Structure and function of Cas-L, a 105-kD Crk-associated substrate-related protein that is involved in beta 1 integrin-mediated signaling in lymphocytes". The Journal of Experimental Medicine 184 (4): 1365–1375. doi:10.1084/jem.184.4.1365. PMC 2192828. PMID 8879209.
13. Astier A, Manié SN, Avraham H, Hirai H, Law SF, Zhang Y, Golemis EA, Fu Y, Druker BJ, Haghayeghi N, Freedman AS, Avraham S (Aug 1997). "The related adhesion focal tyrosine kinase differentially phosphorylates p130Cas and the Cas-like protein, p105HEF1". The Journal of Biological Chemistry 272 (32): 19719–24. doi:10.1074/jbc.272.32.19719. PMID 9242628.
14. Kirsch KH, Georgescu MM, Hanafusa H (Oct 1998). "Direct binding of p130(Cas) to the guanine nucleotide exchange factor C3G". The Journal of Biological Chemistry 273 (40): 25673–9. doi:10.1074/jbc.273.40.25673. PMID 9748234.
15. Garton AJ, Burnham MR, Bouton AH, Tonks NK (Aug 1997). "Association of PTP-PEST with the SH3 domain of p130cas; a novel mechanism of protein tyrosine phosphatase substrate recognition". Oncogene 15 (8): 877–85. doi:10.1038/sj.onc.1201279. PMID 9285683.
16. Liu F, Sells MA, Chernoff J (Jan 1998). "Protein tyrosine phosphatase 1B negatively regulates integrin signaling". Current Biology 8 (3): 173–6. doi:10.1016/s0960-9822(98)70066-1. PMID 9443918.
17. Nakamoto T, Yamagata T, Sakai R, Ogawa S, Honda H, Ueno H, Hirano N, Yazaki Y, Hirai H (Mar 2000). "CIZ, a zinc finger protein that interacts with p130(cas) and activates the expression of matrix metalloproteinases". Molecular and Cellular Biology 20 (5): 1649–58. doi:10.1128/mcb.20.5.1649-1658.2000. PMID 10669742.
18. Harte MT, Hildebrand JD, Burnham MR, Bouton AH, Parsons JT (Jun 1996). "p130Cas, a substrate associated with v-Src and v-Crk, localizes to focal adhesions and binds to focal adhesion kinase". The Journal of Biological Chemistry 271 (23): 13649–55. PMID 8662921.
19. Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, King F, Roberts T, Ratnofsky S, Lechleider RJ (Mar 1993). "SH2 domains recognize specific phosphopeptide sequences". Cell 72 (5): 767–78. doi:10.1016/0092-8674(93)90404-E. PMID 7680959.
20. Law SF, Estojak J, Wang B, Mysliwiec T, Kruh G, Golemis EA (Jul 1996). "Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae". Molecular and Cellular Biology 16 (7): 3327–37. doi:10.1128/mcb.16.7.3327. PMC 231327. PMID 8668148.
21. Sakai R, Iwamatsu A, Hirano N, Ogawa S, Tanaka T, Mano H, Yazaki Y, Hirai H (Aug 1994). "A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner". The EMBO Journal 13 (16): 3748–56. PMC 395286. PMID 8070403.
22. Neumann LC, Weinhäusel A, Thomas S, Horsthemke B, Lohmann DR, Zeschnigk M (2011). "EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation". BMC Cancer 11: 380. doi:10.1186/1471-2407-11-380. PMID 21871071.
23. Tchernev VT, Mansfield TA, Giot L, Kumar AM, Nandabalan K, Li Y, Mishra VS, Detter JC, Rothberg JM, Wallace MR, Southwick FS, Kingsmore SF (Jan 2002). "The Chediak-Higashi protein interacts with SNARE complex and signal transduction proteins". Molecular Medicine 8 (1): 56–64. PMC 2039936. PMID 11984006.
24. O'Neill GM, Fashena SJ, Golemis EA (Mar 2000). "Integrin signalling: a new Cas(t) of characters enters the stage". Trends in Cell Biology 10 (3): 111–9. doi:10.1016/S0962-8924(99)01714-6. PMID 10675905.
25. Alexandropoulos K, Donlin LT, Xing L, Regelmann AG (Apr 2003). "Sin: good or bad? A T lymphocyte perspective". Immunological Reviews 192: 181–95. doi:10.1034/j.1600-065x.2003.00021.x. PMID 12670404.
26. Tikhmyanova N, Tulin AV, Roegiers F, Golemis EA (2010). "Dcas supports cell polarization and cell-cell adhesion complexes in development". PLOS ONE 5 (8): e12369. doi:10.1371/journal.pone.0012369. PMID 20808771.
27. Polte TR, Hanks SK (Nov 1995). "Interaction between focal adhesion kinase and Crk-associated tyrosine kinase substrate p130Cas". Proceedings of the National Academy of Sciences of the United States of America 92 (23): 10678–82. doi:10.1073/pnas.92.23.10678. PMID 7479864.
28. Tornillo G, Defilippi P, Cabodi S (2014). "Cas proteins: dodgy scaffolding in breast cancer". Breast Cancer Research 16 (5): 443. doi:10.1186/s13058-014-0443-5. PMID 25606587.
29. Xing L, Ge C, Zeltser R, Maskevitch G, Mayer BJ, Alexandropoulos K (Oct 2000). "c-Src signaling induced by the adapters Sin and Cas is mediated by Rap1 GTPase". Molecular and Cellular Biology 20 (19): 7363–77. doi:10.1128/mcb.20.19.7363-7377.2000. PMID 10982853.
30. Davidson D, Veillette A (Jul 2001). "PTP-PEST, a scaffold protein tyrosine phosphatase, negatively regulates lymphocyte activation by targeting a unique set of substrates". The EMBO Journal 20 (13): 3414–26. doi:10.1093/emboj/20.13.3414. PMID 11432829.
31. Côté JF, Charest A, Wagner J, Tremblay ML (Sep 1998). "Combination of gene targeting and substrate trapping to identify substrates of protein tyrosine phosphatases using PTP-PEST as a model". Biochemistry 37 (38): 13128–37. doi:10.1021/bi981259l. PMID 9748319.
32. Yang LT, Alexandropoulos K, Sap J (May 2002). "c-SRC mediates neurite outgrowth through recruitment of Crk to the scaffolding protein Sin/Efs without altering the kinetics of ERK activation". The Journal of Biological Chemistry 277 (20): 17406–14. doi:10.1074/jbc.M111902200. PMID 11867627.
33. Tikhmyanova N, Golemis EA (2011). "NEDD9 and BCAR1 negatively regulate E-cadherin membrane localization, and promote E-cadherin degradation". PLOS ONE 6 (7): e22102. doi:10.1371/journal.pone.0022102. PMID 21765937.
34. Nikonova AS, Gaponova AV, Kudinov AE, Golemis EA (Jun 2014). "CAS proteins in health and disease: an update". IUBMB Life 66 (6): 387–95. doi:10.1002/iub.1282. PMID 24962474.
35. Wallez Y, Mace PD, Pasquale EB, Riedl SJ (May 2012). "NSP-CAS Protein Complexes: Emerging Signaling Modules in Cancer". Genes & Cancer 3 (5-6): 382–93. doi:10.1177/1947601912460050. PMID 23226576.
36. He X, Fuller CK, Song Y, Meng Q, Zhang B, Yang X, Li H (May 2013). "Sherlock: detecting gene-disease associations by matching patterns of expression QTL and GWAS". American Journal of Human Genetics 92 (5): 667–80. doi:10.1016/j.ajhg.2013.03.022. PMID 23643380.
37. Bryant PA, Smyth GK, Gooding T, Oshlack A, Harrington Z, Currie B, Carapetis JR, Robins-Browne R, Curtis N (Feb 2014). "Susceptibility to acute rheumatic fever based on differential expression of genes involved in cytotoxicity, chemotaxis, and apoptosis". Infection and Immunity 82 (2): 753–61. doi:10.1128/IAI.01152-13. PMID 24478089.
38. Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, Cantor CR, Young CY (Jun 2009). "Hypermethylation of genes for diagnosis and risk stratification of prostate cancer". Cancer Investigation 27 (5): 549–60. doi:10.1080/07357900802620794. PMID 19229700.
39. Sertkaya S, Hamid SM, Dilsiz N, Varisli L (Feb 2015). "Decreased expression of EFS is correlated with the advanced prostate cancer". Tumour Biology 36 (2): 799–805. doi:10.1007/s13277-014-2703-5. PMID 25296736.
40. Boyer AP, Collier TS, Vidavsky I, Bose R (Jan 2013). "Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers". Molecular & Cellular Proteomics 12 (1): 180–93. doi:10.1074/mcp.M112.020115. PMID 23105007.
41. Tong Y, et al. (2012). "Genomic characterization of human and rat prolactinomas". Endocrinology 153 (8): 3679–91. doi:10.1210/en.2012-1056.
42. Poaty H, Coullin P, Peko JF, Dessen P, Diatta AL, Valent A, Leguern E, Prévot S, Gombé-Mbalawa C, Candelier JJ, Picard JY, Bernheim A (2012). "Genome-wide high-resolution aCGH analysis of gestational choriocarcinomas". PLOS ONE 7 (1): e29426. doi:10.1371/journal.pone.0029426. PMID 22253721.
43. Vital AL, Tabernero MD, Castrillo A, Rebelo O, Tão H, Gomes F, Nieto AB, Resende Oliveira C, Lopes MC, Orfao A (Sep 2010). "Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology". Neuro-Oncology 12 (9): 991–1003. doi:10.1093/neuonc/noq050. PMID 20484145.
44. Xing L, Donlin LT, Miller RH, Alexandropoulos K (May 2004). "The adapter molecule Sin regulates T-cell-receptor-mediated signal transduction by modulating signaling substrate availability". Molecular and Cellular Biology 24 (10): 4581–92. doi:10.1128/mcb.24.10.4581-4592.2004. PMID 15121874.
45. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ (Aug 2008). "Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease". Nature Genetics 40 (8): 955–62. doi:10.1038/ng.175. PMC 2574810. PMID 18587394.
46. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panés J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M (Dec 2010). "Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci". Nature Genetics 42 (12): 1118–25. doi:10.1038/ng.717. PMC 3299551. PMID 21102463.
47. Marques RB, Dits NF, Erkens-Schulze S, van Weerden WM, Jenster G (2010). "Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models". PLOS ONE 5 (10): e13500. doi:10.1371/journal.pone.0013500. PMID 20976069.
48. Nakagawa T, Kollmeyer TM, Morlan BW, Anderson SK, Bergstralh EJ, Davis BJ, Asmann YW, Klee GG, Ballman KV, Jenkins RB (2008). "A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy". PLOS ONE 3 (5): e2318. doi:10.1371/journal.pone.0002318. PMID 18846227.
49. Tahiri A, Røe K, Ree AH, de Wijn R, Risberg K, Busch C, Lønning PE, Kristensen V, Geisler J (2013). "Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma". PLOS ONE 8 (8): e72692. doi:10.1371/journal.pone.0072692. PMID 24023633.
50. Røe K, Bratland Å, Vlatkovic L, Ragnum HB, Saelen MG, Olsen DR, Marignol L, Ree AH (2013). "Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer". PLOS ONE 8 (5): e63723. doi:10.1371/journal.pone.0063723. PMID 23675504.